Koji Teraishi

Title: Koji Teraishi: Innovator in NK Cell Therapies

Introduction

Koji Teraishi is a prominent inventor based in Fukuoka, Japan. He has made significant contributions to the field of immunotherapy, particularly in the development of highly active natural killer (NK) cells. His work focuses on enhancing the efficacy of NK cell therapies, which hold great promise for treating various diseases.

Latest Patents

Teraishi holds 2 patents related to his innovative work. His latest patent, titled "Highly active NK cell and use thereof," describes an NK cell exhibiting higher cytotoxic activity. The invention aims to provide a pharmaceutical composition for NK cell therapies that are expected to be highly effective. The NK cells characterized in this patent possess specific traits: they are CD16-positive, highly express CD56, and are CD57-negative. Additionally, these NK cells are NKG2C-positive, NKG2A-negative or lowly express NKG2A, and are CD94-positive. The patent also includes a pharmaceutical composition containing a population of such NK cells along with a therapeutically effective amount of antibodies.

Career Highlights

Throughout his career, Koji Teraishi has worked with various organizations, including Gaia Biomedicine Inc. and Yoshikazu Yonemitsu. His expertise in the field of immunotherapy has positioned him as a key figure in advancing NK cell research and applications.

Collaborations

Teraishi has collaborated with notable individuals in his field, including Yoshikazu Yonemitsu and Yui Harada. These collaborations have contributed to the development of innovative therapies and have furthered research in NK cell applications.

Conclusion

Koji Teraishi's contributions to the field of NK cell therapies highlight his role as an influential inventor. His patents and collaborative efforts continue to pave the way for advancements in immunotherapy, showcasing the potential of NK cells in medical treatments.